GlassScriptPhysician profile
Ataul M Qureshi
NPI 1992013338
$6,467.18
in general payments reported to CMS, 2019-2025
16 companies · $4,020 in 2025
The $4,020 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,642 · 2020: $65.53 · 2021: $40.80 · 2022: $126 · 2023: $353 · 2024: $220 · 2025: $4,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,914 · Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,913.71 |
| Food and Beverage | $1,678.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,603.45 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Triclip |
| Abiomed | $1,366.89 | 2022-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $173.69 | 2019-2024 | Lifevest |
| Edwards Lifesciences Corporation | $61.48 | 2025 | Pascal |
| Astrazeneca Pharmaceuticals LP | $48.11 | 2023-2024 | Wainua |
| Alnylam Pharmaceuticals INC. | $35.06 | 2019 | |
| Amgen INC. | $28.77 | 2019-2020 | |
| Genzyme Corporation | $23.55 | 2019 | |
| Ge Healthcare | $21.82 | 2021 | |
| Merck Sharp & Dohme LLC | $20.90 | 2023 | |
| Lantheus Medical Imaging, INC. | $19.78 | 2024 | |
| Livanova USA, INC. | $19.14 | 2023 | Lifesparc |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.64 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.20 | 2023 | |
| Janssen Pharmaceuticals, INC | $11.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ataul Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.